B-FLEXION Life Sciences Acquires Majority Stake in Radius Health, Consolidating Ownership of TYMLOS Osteoporosis Treatment
Key Insights
B-FLEXION Life Sciences (search) has agreed to purchase the remaining 57% interest in Radius Health (search) from Patient Square Capital (search) and Webster Equity Partners (search), consolidating ownership of the osteoporosis (search)-focused biopharmaceutical company.
The transaction follows three years of accelerated growth and successful commercialization of TYMLOS (abaloparatide), an FDA-approved treatment for postmenopausal women and men with osteoporosis (search) at high risk for fracture.
Radius Health (search) has undergone significant transformation since the 2022 take-private transaction, with leadership emphasizing sustained growth and expanded patient access to their lead bone health therapy.
B-FLEXION Life Sciences (search) has agreed to acquire the remaining 57% interest in Radius Health (search) from Patient Square Capital (search) and Webster Equity Partners (search), consolidating ownership of the specialty biopharmaceutical company focused on bone health therapeutics. The transaction, announced January 12, 2026, follows three years of accelerated growth and successful operations since B-FLEXION and Patient Square's initial take-private acquisition of Radius in August 2022.
Strategic Consolidation After Three Years of Growth
The acquisition represents a significant milestone for Radius Health (search), which has undergone substantial transformation under its current ownership structure. Scott Briggs, Chief Executive Officer of Radius Health, emphasized the company's evolution, stating, "Over the past three years, Radius has undergone a significant transformation, sharpening our focus on commercialization and delivering sustained growth. We are grateful for the support our partners have provided, which has enabled us to deliver TYMLOS to an increasing number of patients living with osteoporosis (search)."
The consolidation comes as Radius has demonstrated strong commercial performance with its lead product TYMLOS (abaloparatide) injection, a parathyroid hormone-related peptide approved by the U.S. Food and Drug Administration for treating postmenopausal women and men with osteoporosis (search) at high risk for fracture.
TYMLOS Commercial Success Drives Transaction
Nithya Desikan, Operating Partner at B-FLEXION Life Sciences (search) and Member of the Board at Radius, highlighted the commercial achievements that have driven the acquisition decision. "We are extremely proud of the momentum of what has become a strong, profitable business within our portfolio," Desikan said. "The team has built incredible commercial capabilities, and we look forward to continuing the success of TYMLOS as it provides meaningful impact to the patients and families we serve."
TYMLOS is specifically indicated for patients with a history of osteoporotic fracture or multiple risk factors for fracture, as well as those who have failed or are intolerant to other available osteoporosis (search) therapies. The treatment addresses a significant unmet medical need in bone health, particularly for high-risk patient populations.
Investment Thesis Validation
Jim Momtazee, Managing Partner of Patient Square, described the transaction as a validation of the initial investment strategy. "We are proud of the transformation achieved at Radius over the past three years by Scott and his team expanding the impact of an important medicine," Momtazee stated. "With our initial investment thesis playing out as expected and with a bright future ahead, it is a good time to deliver returns for our investors and consolidate ownership of the Company for its next stage of growth."
The transaction structure allows Patient Square to realize returns on its investment while enabling B-FLEXION to assume full control of Radius's continued development and commercialization efforts.
Transaction Details and Timeline
The acquisition is expected to close by the end of the first quarter of 2026, with Centerview Partners LLC serving as financial advisor to Radius Health (search). The consolidation positions B-FLEXION Life Sciences (search) as the sole owner of Radius, providing strategic clarity for the company's future growth initiatives in bone health and related therapeutic areas.
B-FLEXION Life Sciences (search), part of the broader B-FLEXION group with offices across Europe and the United States, focuses on principal investments in biotech, therapeutics, diagnostics, and physician practice management. The firm applies active ownership principles, working closely with portfolio company management teams to achieve key value inflection points while bringing safe and effective treatments to market.